Replies to post #204494 on Biotech Values

[mcbio]

SRPT -

With their balance sheet I wouldn't bet on them doing a significant deal at this point. I think their priority would be to develop their next generation PMO's. Art Krieg (who should know) on twitter said they should be significantly more potent/better uptake.

Couple of comments:

1. They just announced AH plans for a $225M offering. They can also raise significant money by selling their priority review voucher (assume $100M+ based on recent sales).

2. It would not be prohibitively expensive at all to acquire one of the other DMD small-cap plays given small valuations and there are at least a few private players that I assume would be cheap as well.

3. Beyond an outright acquisition of another DMD company, they could choose to spend a lot less to just acquire rights to another DMD drug to combine with Exondys (and rest of internal pipe).

4. Finally, that article I linked contains quotes straight from the horse's mouth (CEO Ed Kaye). If he previously said he had plans for his company to look to acquire other DMD drugs, I have to take him at face value (SRPT was in much weaker position at the time to go through with such a plan).